Cambiar Investors’s NovoCure NVCR Stock Holding History

Cambiar Investors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-65,479	Closed	-$2.19M	–	168
2018 Q4	$2.19M	Buy	+65,479	New	+$2.39M	0.05%	147

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cambiar Investors's NVCR Position: Q1 2019 in Review

Cambiar Investors sold out of NovoCure (NVCR) in Q1 2019, closing a stake of 65,479 shares — an estimated $2.19M sold.

Cambiar Investors first reported a position in NVCR in Q4 2018 and held it in 1 quarter. The position peaked at $2.19M in Q4 2018. 200 funds tracked by Wall St. Rank hold NVCR as of Q1 2019.

Cambiar Investors reported no remaining NovoCure position as of Q1 2019 after selling out during the quarter.
Cambiar Investors sold 65,479 NovoCure shares in Q1 2019, an estimated $2.19M.
Cambiar Investors first reported a position in NovoCure in Q4 2018 and held it in 1 quarter.
Cambiar Investors's NovoCure position peaked at $2.19M in Q4 2018.
200 funds tracked by Wall St. Rank held NovoCure as of Q1 2019.

Based on Cambiar Investors's 13F filing for Q1 2019, filed 8 May 2019.